Karzis J, Donkin E F, Petzer I M
Department of Production Animal Studies, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, South Africa.
Onderstepoort J Vet Res. 2007 Sep;74(3):243-9. doi: 10.4102/ojvr.v74i3.127.
The length of the antibiotic withdrawal period after intramammary treatment was influenced by the milk yield of dairy goats during this trial. Shorter withdrawal periods were seen in relatively high yielding dairy goats (production above 1.5 l per day) compared to low producers (less than 1.3 l per day). High yielding goats treated with Curaclox LC (Norbrook [Pharmacia AH]) had a withdrawal period of 42 h, while low yielding goats, treated with the same product, had a withdrawal period of 74 h. The recommended withdrawal period for Curaclox LC for use in cattle is 72 h. Relatively high yielding goats treated with Rilexine 200 LC (Logos Agvet [Virbac]) had a significantly shorter withdrawal period (37 h) than that recommended for use in cattle (96 h). Low yielding goats treated with Spectrazol Milking Cow (Schering-Plough Animal Health) had a significantly longer (95 h) withdrawal period than that recommended for use in cattle (60 h). Withdrawal periods were also influenced by stage of lactation and parity. There was a moderate positive correlation between lactation number and withdrawal period, as measured by TRIS (R2 = 0.621), and a moderate negative correlation between stage of lactation and withdrawal period (R2 = -0.669). In Trials 1, 2 and 3 combined there was a moderate negative correlation between withdrawal period and volume (R2 = -0.511) and a strong positive correlation between withdrawal period and lactation number (R2 = 0.720). The differences in percentage milk fat, protein and lactose before, during and after treatment were not statistically significant except in Trial 3 (Curaclox LC and Rilexine 200 LC) where protein and lactose differed significantly. In Trial 2 (Spectrazol Milking Cow) milk fat percentages differed significantly between treatment and control groups as did protein percentages in Trial 3. These differences are however, not biologically meaningful.
在本次试验中,乳房内治疗后抗生素停药期的长短受奶山羊产奶量的影响。与低产奶山羊(每天产奶量低于1.3升)相比,相对高产的奶山羊(每天产奶量高于1.5升)的停药期较短。用Curaclox LC(诺布鲁克[法玛西亚AH])治疗的高产奶山羊停药期为42小时,而用同一产品治疗的低产奶山羊停药期为74小时。Curaclox LC用于牛的推荐停药期为72小时。用Rilexine 200 LC(洛戈斯农业兽医[维克])治疗的相对高产奶山羊的停药期(37小时)明显短于用于牛的推荐停药期(96小时)。用Spectrazol Milking Cow(先灵葆雅动物保健)治疗的低产奶山羊的停药期(95小时)明显长于用于牛的推荐停药期(60小时)。停药期还受泌乳阶段和胎次的影响。通过TRIS测量,泌乳次数与停药期之间存在中度正相关(R2 = 0.621),泌乳阶段与停药期之间存在中度负相关(R2 = -0.669)。在试验1、2和3合并的情况下,停药期与奶量之间存在中度负相关(R2 = -0.511),停药期与泌乳次数之间存在强正相关(R2 = 0.720)。除试验3(Curaclox LC和Rilexine 200 LC)中蛋白质和乳糖有显著差异外,治疗前、治疗期间和治疗后乳脂肪、蛋白质和乳糖百分比的差异无统计学意义。在试验2(Spectrazol Milking Cow)中,治疗组和对照组之间的乳脂肪百分比有显著差异,试验3中的蛋白质百分比也有显著差异。然而,这些差异在生物学上并无意义。